Metformin-containing Drugs: Drug Safety Communication – Revised Warnings for Certain Patients With Reduced Kidney Function – April 8, 2016
After further review by the United States Food and Drug Administration, metformin labeling has been changed, liberalizing recommendations regarding the use of this drug in patients with mild to moderate kidney impairment. This inexpensive, efficacious first-line medication for use in treating patients with Type II Diabetes Mellitus is now judged to be safe in a broader array of patients. This is especially good news among elderly patients. Full details are available through the following link to FDA 2016 safety alerts.
WARNING: None of the information on this website should be construed as medical advice. Such advice is always individualized and should come directly from your own personal physician